Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Hay

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Blood|April 18, 2009
A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3Megan S Sutherland, Anthony M Cumming, Mackenzie Bowman, et al.
Journal of Thrombosis and Haemostasis : JTH|June 29, 2004
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99S C Darby, D M Keeling, R J D Spooner, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 23, 2020
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical companyCharles R M Hay, Midori Shima, Michael Makris, et al.
Journal of Thrombosis and Haemostasis : JTH|August 29, 2018
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophiliaR A Gruppo, D Malan, J Kapocsi, et al.
Research and Practice in Thrombosis and Haemostasis|October 6, 2025
Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors' OrganisationCaroline Wall, Hua Xiang, Ben Palmer, et al.
Blood|April 21, 2007
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIVSarah C Darby, Sau Wan Kan, Rosemary J Spooner, et al.
Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting databaseSteven W Pipe, Rebecca Kruse-Jarres, Johnny N Mahlangu, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 17, 2004
Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' OrganizationK J Pasi, P W Collins, D M Keeling, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 24, 2017
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patientsP W Collins, D V K Quon, M Makris, et al.
Journal of Thrombosis and Haemostasis : JTH|July 23, 2025
Impaired tolerance in the International Immune Tolerance Induction study due to the presence of very low-titer inhibitorsLars L F G Valke, Charles R M Hay, Donna M DiMichele, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Blood|April 18, 2009
A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3Megan S Sutherland, Anthony M Cumming, Mackenzie Bowman, et al.
Journal of Thrombosis and Haemostasis : JTH|June 29, 2004
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99S C Darby, D M Keeling, R J D Spooner, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 23, 2020
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical companyCharles R M Hay, Midori Shima, Michael Makris, et al.
Journal of Thrombosis and Haemostasis : JTH|August 29, 2018
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophiliaR A Gruppo, D Malan, J Kapocsi, et al.
Research and Practice in Thrombosis and Haemostasis|October 6, 2025
Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors' OrganisationCaroline Wall, Hua Xiang, Ben Palmer, et al.
Blood|April 21, 2007
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIVSarah C Darby, Sau Wan Kan, Rosemary J Spooner, et al.
Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting databaseSteven W Pipe, Rebecca Kruse-Jarres, Johnny N Mahlangu, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 17, 2004
Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' OrganizationK J Pasi, P W Collins, D M Keeling, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 24, 2017
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patientsP W Collins, D V K Quon, M Makris, et al.
Journal of Thrombosis and Haemostasis : JTH|July 23, 2025
Impaired tolerance in the International Immune Tolerance Induction study due to the presence of very low-titer inhibitorsLars L F G Valke, Charles R M Hay, Donna M DiMichele, et al.
Pageof 6